IP Library › Granted Patent US 8,900,819
Granted Patent B2
US 8,900,819 · App. 13/286,820 · Granted Dec 2, 2014

ADRB2 cancer markers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,900,819
App. No.
13/286,820
Granted
Dec 2, 2014
Kind
B2
Abstract

The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ADRB2 markers for cancer.

Claims (5)

1. A method for identifying risk of prostate cancer recurrence in a prostate cancer patient, comprising:

a) detecting the level of expression of Adrenergic Receptor, Beta 2 (ADRB2) polypeptide compared to normal expression of ADRB2 polypeptide in a prostate cancer biopsy sample from a patient diagnosed with prostate cancer by detecting the binding of an antibody that specifically binds to an ADRB2 polypeptide using an immunoassay;

b) comparing the level of expression of ADRB2 polypeptide in said sample to the level in a sample of normal prostate tissue; and

c) identifying said patient as being at risk of recurrence of prostate cancer when said expression level is decreased relative to the level in normal prostate tissue.

2. The method of claim 1 , wherein said recurrence of disease after prostatectomy comprises development of metastatic cancer.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 6, 2011
From: UNIVERSITY OF MICHIGAN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027334/0233 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2011
From: CHINNAIYAN, ARUL M.; YU, JINDAN; MEHRA, ROHIT
To: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 027216/0024 →